New mRNA HIV vaccine trial aims to train immune system to fight virus

NCT ID NCT06557785

Ongoing ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests two experimental mRNA vaccines designed to teach the body to make powerful antibodies that can neutralize many types of HIV. About 53 healthy adults without HIV will receive the vaccines to check safety and immune response. The goal is to see if the vaccines are safe and can start building a defense against HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (Site ID: 32077)

Boston, Massachusetts, 02215, United States
Columbia P&S (Site ID: 30329)

New York, New York, 10032, United States
New York Blood Center (Site ID: 31801)

New York, New York, 10065, United States
Penn Prevention (Site ID: 30310)

Philadelphia, Pennsylvania, 19104, United States
Seattle Vaccine and Prevention (Site ID: 30331)

Seattle, Washington, 98104, United States
University of Pittsburgh (Site ID: 1001)

Pittsburgh, Pennsylvania, 15213, United States
Vaccine Trial Centre, Mahidol University CRS (Site ID: 32021)

Bangkok, Ratchathewi, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.